tradingkey.logo

Y-mAbs Therapeutics Inc <YMAB.OQ> expected to post a loss of 12 cents a share - Earnings Preview

ReutersFeb 28, 2025 1:48 PM
  • Y-mAbs Therapeutics Inc YMAB.OQ YMAB.O is expected to show a rise in quarterly revenue when it reports results on March 4 for the period ending December 31 2024

  • The New York City-based company is expected to report a 16.8% increase in revenue to $27.29 million from $23.36 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Y-mAbs Therapeutics Inc is for a loss of 12 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $21.50​, above​ its last closing price of $5.42. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.16

-0.16

-0.16

Met

-1.6

Jun. 30 2024

-0.13

-0.13

-0.21

Missed

-59.8

Mar. 31 2024

-0.14

-0.14

-0.15

Missed

-10.5​

Dec. 31 2023

-0.20

-0.20

-0.02

Beat

90.1

​​Sep. 30 2023

-0.18

-0.19

-0.18

Beat

3.7

Jun. 30 2023

-0.24

-0.24

-0.14

Beat

42.1​

Mar. 31 2023

-0.32

-0.32

-0.15

Beat

52.9

Dec. 31 2022

-0.44

-0.46

0.03

Beat

106.6

This summary was machine generated February 28 at 13:48 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI